

Application Number 10/698,881  
Response to Office Action mailed September 13, 2007

**RECEIVED  
CENTRAL FAX CENTER**

DEC 07 2007

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

Claims 1-18 (Canceled).

Claim 19 (Previously Presented): A method of providing medical therapy to a patient, the method comprising delivering a training sequence of stimulation pulses to a prostate gland via an implantable medical device, wherein the implantable medical device includes one or more electrodes that are deployed on or implanted within cellular muscle tissue of the prostate gland, the training sequence being defined to change a fiber structure of the prostate gland, wherein the training sequence defines a first pulse train and a second pulse train, wherein the first pulse train and the second pulse train are each delivered over time periods on an order of a week, the second pulse train being delivered after the first pulse train, wherein the second pulse train includes more pulses per unit time than the first pulse train.

Claim 20 (Original): The method of claim 19, further comprising delivering the training sequence to relax the fiber structure of the prostate gland.

Claim 21 (Original): The method of claim 19, wherein the pulses define pulse widths between approximately 10 and 500 microseconds, amplitudes less than approximately 10.5 volts, frequencies between approximately 2 and 20 hertz, and pulse intervals between approximately 10 and 500 milliseconds.

Claim 22 (Original): The method of claim 19, further comprising delivering drugs to the prostate gland in conjunction with delivering the one or more therapeutic stimulation pulses.

Claims 23-27 (Canceled).

Application Number 10/698,881  
Response to Office Action mailed September 13, 2007

Claim 28 (Currently amended): An implantable ~~implanted~~ medical device comprising:

means for generating a training sequence of therapeutic stimulation pulses;

means for delivering the training sequence of therapeutic stimulation pulses to a prostate gland such that the training sequence of therapeutic stimulation pulses cause a fiber structure of the prostate gland to change, wherein the training sequence defines a first pulse train and a second pulse train, wherein the first pulse train and the second pulse train are each delivered over time periods on an order of a week, the second pulse train being delivered after the first pulse train, wherein the second pulse train includes more pulses per unit time than the first pulse train, wherein means for delivering the training sequence includes one or more electrodes that are deployed on or implanted within cellular muscle tissue of the prostate gland.

Claim 29 (Currently amended): The implantable ~~implanted~~ medical device of claim 28, wherein the training sequence of therapeutic stimulation pulses cause the fiber structure of the prostate gland to relax.

Claims 30-32 (Canceled).

Claim 33 (Previously Presented): A method of providing medical therapy to a patient, the method comprising:

delivering a first pulse train to a prostate gland over a first period of time; and

delivering a second pulse train to the prostate gland over a second period of time, wherein the second pulse train is different than the first pulse train, and wherein delivering the first and second pulse trains causes a fiber structure of the prostate gland to change, wherein the first pulse train and the second pulse train are each delivered over time periods on an order of a week, wherein the first and second pulse trains are delivered via one or more electrodes deployed on or implanted within cellular muscle tissue of the prostate gland.

Claim 34 (Original): The method of claim 33, wherein the second pulse train defines a pulse rate that is higher than that of the first pulse train.

Application Number 10/698,881  
Response to Office Action mailed September 13, 2007

Claim 35 (Original): The method of claim 33, further comprising delivering a third pulse train to the prostate gland over a third period of time, wherein the third pulse train is different than the first or second pulse train, and wherein delivering the first, second and third pulse trains causes a fiber structure of the prostate gland to change.

Claim 36 (Original): The method of claim 35, further comprising delivering a fourth pulse train to the prostate gland over a fourth period of time, wherein the fourth pulse train is different than the first, second or third pulse train, and wherein delivering the first, second, third and fourth pulse trains causes a fiber structure of the prostate gland to change.

Claim 37 (Original): The method of claim 36, wherein the fourth pulse train defines a fourth pulse rate that is higher than that of the third pulse train, the third pulse train defines a third pulse rate that is higher than that of the second pulse train and the second pulse train defines a second pulse rate that is higher than that of the first pulse train.

Claims 38-40 (Canceled).

Application Number 10/698,881  
Response to Office Action mailed September 13, 2007

Claim 41 (Currently amended): An implantable medical device comprising:

one or more leads including one or more electrodes for implantation adjacent a prostate gland within cellular muscle tissue of the prostate gland;

a pulse generator to generate therapeutic stimulation pulses and deliver the pulses to the one or more electrodes via the one or more leads; and

a processor configured to control the therapy delivery circuit such that the therapeutic stimulation pulses define a training sequence which causes a fiber structure of the prostate gland to change, wherein the training sequence defines a first pulse train and a second pulse train, wherein the first pulse train and the second pulse train are each delivered over time periods on an order of a week, the second pulse train being delivered after the first pulse train, wherein the second pulse train includes more pulses per unit time than the first pulse train.

Claim 42 (Previously Presented): The implantable medical device of claim 41, wherein the training sequence causes the fiber structure of the prostate gland to relax.

Claim 43 (New): The implantable medical device of claim 41, wherein the pulses define pulse widths between approximately 10 and 500 microseconds, amplitudes less than approximately 10.5 volts, frequencies between approximately 2 and 20 hertz, and pulse intervals between approximately 10 and 500 milliseconds.